Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HH103
- Development stage
- Preclinical
- Lead developer
- Hedgehog Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
HH103 is a preclinical-stage monoclonal antibody being developed by Hedgehog Technology for the treatment of solid cancers. It specifically targets the human Endothelin A Receptor (ETAR). By competitively inhibiting the binding between ETAR and its ligand, endothelin, HH103 blocks endothelin-mediated signaling pathways that are implicated in tumor growth, survival, and progression. The drug is part of a pipeline focused on disrupting the Hedgehog signaling pathway and related oncogenic drivers. HH103 is currently in the early discovery or 'Hit' stage of development.
- Other names
- anti-human ETAR monoclonal antibodyanti-ETAR mAb
02
Targets
EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on HH103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HH103.